| Literature DB >> 35509515 |
Abayeneh Girma1, Aleka Aemiro1.
Abstract
Urinary tract infection remains the most common infection widespread worldwide in both community and hospital settings. Rapidly increasing antibiotic resistance of uropathogens is resulting in limited treatment options. Thus, understanding the current uropathogens and their antimicrobial susceptibilities is essential for effective urinary tract infection treatment. The purpose of this study was to isolate, characterize, and determine the antimicrobial susceptibility patterns of bacterial pathogens associated with urinary tract infection at Pawe General Hospital in Northwest Ethiopia. A hospital-based cross-sectional study design was conducted from January to April, 2020, at Pawe General Hospital. Midstream urine specimens were collected from 141 individuals with suspected urinary tract infection for bacteriological identification and antimicrobial susceptibility testing. Among the 141 study participants, twenty-nine (20.6%) showed significant bacteriuria. Escherichia coli (42.6%) had the highest proportion of isolated uropathogen followed by Klebsiella spp. and Pseudomonas spp. each (10.7%); Proteus spp. (9.3%); coagulase negative staphylococci, Staphylococcus aureus, and Enterobacter spp. each (6.7%); Citrobacter spp. (4%); and Enterococcus faecalis and Streptococcus spp. each (1.3%). Outpatient isolates showed a resistance of 64% and 78.6% to amoxicillin-clavulanic acid and tetracycline, respectively. Inpatients showed 63.9% and 87.2% of resistance to cephalexin and tetracycline. It was also observed that all the isolates have a multiple antimicrobial resistance index greater than 0.20 except Citrobacter spp. (0.142) in inpatients. Even though in this locality, most isolates were sensitive to ceftriaxone, gentamicin, ciprofloxacin, nitrofurantoin, and norfloxacin, they are considered appropriate antimicrobials for empirical treatment of urinary tract bacterial infections. Periodic monitoring of etiology and drug susceptibility is highly recommended, along with health education on the transmission and causes of urinary tract infection.Entities:
Year: 2022 PMID: 35509515 PMCID: PMC9061053 DOI: 10.1155/2022/3085950
Source DB: PubMed Journal: Scientifica (Cairo) ISSN: 2090-908X
Distribution of uropathogens in patients.
| Urinary tract bacterial isolates | Number of isolates (N) | Percentage (%) | ||
|---|---|---|---|---|
| Inpatient | Outpatient | Inpatient | Outpatient | |
|
| 21 | 11 | 33.60 | 32.50 |
|
| 5 | 3 | 15.81 | 15.00 |
|
| 4 | 3 | 13.84 | 13.50 |
|
| 5 | 3 | 9.88 | 11.00 |
| CNS | 3 | 2 | 7.91 | 9.00 |
|
| 3 | 2 | 6.72 | 6.50 |
|
| 3 | 2 | 5.92 | 5.50 |
|
| 2 | 1 | 3.95 | 3.50 |
|
| 1 | 0 | 2.37 | 2.00 |
|
| 0 | 1 | 0.0 | 1.50 |
| Total | 47 | 28 | 100% | 100% |
CNS : coagulase negative staphylococci.
Antimicrobial susceptibility pattern of uropathogens isolated from urine specimens of inpatients.
| Bacterial pattern | Isolates | Antimicrobial susceptibility pattern, | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin/C | Cephalothin | Ceftriaxone | Tetracycline | Gentamicin | Ciprofloxacin | Nitrofurantoin | Norfloxacin | ||
|
| S | — | 5 (23.8) | 8 (38.1) | 1 (4.8) | 19 (90.4) | 21 (100) | 21 (100) | 21 (100) |
| I | — | 1 (4.8) | 1 (4.8) | 1 (4.8) | 1 (4.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 15 (71.4) | 12 (57.1) | 19 (90.4) | 1 (4.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 2 (40) | 3 (60) | 0 (0.0) | 4 (80) | 5 (100) | 5 (100) | 5 (100) |
| I | — | 1 (20) | 0 (0.0) | 1 (20) | 1 (20) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (40) | 2 (40) | 4 (80) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 2 (50) | 2 (50) | 0 (0.0) | 3 (75) | 4 (100) | 4 (100) | 4 (100) |
| I | — | 0 (0.0) | 1 (25) | 1 (25) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (50) | 1 (25) | 3 (75) | 1 (25) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 0 (0.0) | 1 (20) | 0 (0.0) | 3 (60) | 4 (80) | 3 (60) | 3 (60) |
| I | — | 1 (20) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (20) | 2 (40) | 1 (20) | |
| R | — | 4 (80) | 4 (80) | 5 (100) | 2 (40) | 0 (0.0) | 0 (0.0) | 1 (20) | |
|
| |||||||||
| CNS ( | S | — | 1 (33.3) | 2 (66.7) | 0 (0.0) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
| I | — | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (66.7) | 1 (33.3) | 3 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 1 (33.3) | 2 (66.7) | 0 (0.0) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) |
| I | — | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (66.7) | 1 (33.3) | 2 (66.7) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 1 (33.3) | 2 (66.7) | 0 (0.0) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
| I | — | 0 (0.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (66.7) | 0 (0.0) | 2 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 0 | 1 (50) | 0 (0.0) | 1 (50) | 2 (100) | 2 (100) | 2 (100) |
| I | — | 2 (100) | 1 (50) | 0 (0.0) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 0 (0.0) | 0 (0.0) | 2 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
| I | — | 0 (0.0) | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 1 (100) | 0 (0.0) | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| I | — | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
| Total, | S | — | 12 (25.5) | 21 (44.7) | 1 (2.2) | 39 (83.0) | 46 (97.9) | 45 (95.8) | 45 (95.8) |
| I | — | 5 (10.6) | 5 (10.6) | 5 (10.6) | 3 (6.4) | 1 (2.1) | 2 (4.2) | 1 (2.1) | |
| R | — | 30 (63.9) | 21 (44.7) | 41 (87.2) | 5 (10.6) | 0 (0.0) | 0 (0.0) | 1 (2.1) | |
S: number of sensitive; I: number of intermediate; R: number of resistant isolates; -antibiotic was not used.
Antimicrobial susceptibility pattern of uropathogens isolated from urine specimens of outpatients.
| Bacterial isolates | Pattern | Antimicrobial susceptibility pattern, | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin/C | Cephalothin | Ceftriaxone | Tetracycline | Gentamicin | Ciprofloxacin | Nitrofurantoin | Norfloxacin | ||
|
| S | 2 (18.2) | 2 (18.2) | 2 (18.2) | 0 (0.0) | 9 (81.8) | 10 (90.9) | 11 (100) | 11 (100) |
| I | 3 (27.3) | 3 (27.3) | 5 (45.4) | 2 (18.2) | 2 (18.2) | 1 (9.1) | 0 (0.0) | 0 (0.0) | |
| R | 6 (54.5) | 6 (54.5) | 4 (36.4) | 9 (81.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) |
| I | 1 (33.3) | 0 (0.0) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 2 (66.7) | 2 (66.7) | 0 (0.0) | 2 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 2 (66.7) | 2 (66.7) | 0 (0.0) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) |
| I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 3 (100) | 1 (33.3) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | — | 0 (0.0) | 1 (33.3) | 0 (0.0) | 2 (66.7) | 3 (100) | 3 (100) | 2 (66.7) |
| I | — | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | — | 2 (66.7) | 2 (66.7) | 3 (100) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (33.3) | |
|
| |||||||||
| CNS ( | S | 1 (50) | 1 (50) | 1 (50) | 0 (0.0) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
| I | 0 (0.0) | 1 (50) | 0 (0.0) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 1 (50) | 0 (0.0) | 1 (50) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 1 (50) | 0 (0.0) | 2 (100) | 0 (0.0) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
| I | 0 (0.0) | 1 (50) | 0 (0.0) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 1 (50) | 1 (50) | 0 (0.0) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 1 (50) | 2 (100) | 0 (0.0) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
| I | 1 (50) | 1 (50) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 1 (50) | 0 (0.0) | 0 (0.0) | 2 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 0 (0.0) | 1 (100) | 0 (0.0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
| I | 0 (0.0) | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 1 (100) | 0 (0.0) | 0 (0.0) | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
|
| S | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
| I | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| R | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||||||
| Total, | S | 4 (16) | 7 (25.0) | 13 (46.4) | 0 (0.0) | 23 (82.1) | 27 (96.4) | 28 (100) | 27 (96.4) |
| I | 5 (20) | 8 (28.6) | 6 (21.5) | 6 (21.4) | 4 (14.3) | 1 (3.6) | 0 (0.0) | 0 (0.0) | |
| R | 16 (64) | 13 (46.4) | 9 (32.1) | 22 (78.6) | 1 (3.6) | 0 (0.0) | 0 (0.0) | 1 (3.6) | |
S: number of sensitive; I: number of intermediate; R: number of resistant isolates; -antibiotic was not used.
Multiple antimicrobial resistance indexes of uropathogens isolated from inpatients.
| Isolates |
|
| MARI = (a/ | Antibiotics to which the isolates are resistant |
|---|---|---|---|---|
|
| 4 | 7 | 0.571 | CEPH, CRO, TE, and CN |
|
| 3 | 7 | 0.428 | CEPH, CRO, and TE |
|
| 4 | 7 | 0.571 | CEPH, CRO, TE, and CN |
|
| 5 | 7 | 0.714 | CEPH, CRO, TE, CN, and NOR |
| CNS | 3 | 7 | 0.428 | CEPH, CRO, and TE |
|
| 4 | 7 | 0.571 | CEPH, CRO, TE, and CN |
|
| 2 | 7 | 0.285 | CEPH, and TE |
|
| 1 | 7 | 0.142 | TE |
|
| 2 | 7 | 0.285 | CEPH, and TE |
|
| — | — | — | — |
Total number of antibiotics tested = 7; CEPH : cephalexin; CRO : ceftriaxone; TE : tetracycline; CN : gentamicin; CIP : ciprofloxacin; F : nitrofurantoin; NOR : norfloxacin.
Multiple antimicrobial resistance indexes of uropathogens isolated from outpatients.
| Isolates |
|
| MARI = (a/ | Antibiotics to which the isolates are resistant |
|---|---|---|---|---|
|
| 4 | 8 | 0.500 | AMC, CEPH, CRO, and TE |
|
| 3 | 8 | 0.375 | AMC, CEPH, and TE |
|
| 4 | 8 | 0.500 | AMC, CEPH, CRO, and TE |
|
| 5 | 8 | 0.625 | CEPH, CRO, TE, CN, and NOR |
| CNS | 3 | 8 | 0.375 | AMC, CRO, and TE |
|
| 3 | 8 | 0.375 | AMC, CEPH, and TE |
|
| 2 | 8 | 0.250 | AMC, and TE |
|
| 2 | 8 | 0.250 | AMC, and TE |
|
| — | — | — | — |
|
| 4 | 8 | 0.500 | AMC, CEPH, CRO, and TE |
Total number of antibiotics tested = 8; AMC: amoxicillin/clavulanic acid; CEPH : cephalexin; CRO : ceftriaxone; TE : tetracycline; CN : gentamicin; CIP : ciprofloxacin; NFN : nitrofurantoin; NOR : norfloxacin.